Trending Now
Intellia Therapeutics Inc. (NASDAQ:NTLA) And Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Expand Their...
Intellia Therapeutics Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have announced an expansion to their current collaboration for the development of CRISPR/Cas9 treatments.
Collaboration to...
The Launch of AditxtScore™ for COVID-19 by Aditxt, Inc. (NASDAQ: ADTX)...
Several states, including Kentucky, are still experiencing a dramatic surge in COVID-19 cases. In addition, hospitals and caregivers are feeling the heat due to...
The FDA Grants Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) Fast Track Designation...
There is an urgent need to expedite the review of drugs to treat severe or life-threatening conditions, including autosomal dominant polycystic kidney disease, cancer,...
Popular News
Pitney Bowes Inc. (NYSE: PBI) Reports a 7% Revenue Growth in...
Pitney Bowes Inc. (NYSE: PBI), an eCommerce company, recently released its financial and operational results for the second quarter of 2021. The company reported...
MAKE IT MODERN
LATEST REVIEWS
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) Announced Data For BCX9930 Clinical Trial In...
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) has released new data from the treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH)patients. This is for the patients who receive doses via...
MAKE IT MODERN
PERFORMANCE TRAINING
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Releases Cohort 4 C-144-01 Study Data In Advanced Melanoma
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) has announced preliminary data from vital Cohort 4 as well as updated Cohort 2 data in its C-144-01 lifileucel study...
NovaBay Pharmaceuticals (NYSE:NBY) Reports Revenues Of $1.9 Million In Q4 2020: Targets Beauty Market...
NovaBay Pharmaceuticals (NYSE:NBY) reported a growth of 10% YoY in Q4 2020 revenues to $1.9 million. Its full-year revenues are $9.9 million (up 51%...
Agios Pharmaceutical (NASDAQ:AGIO) Withdrawals European MAA For TIBSOVO® In Treating Refractory/Relapsed IDH1-Mutant AML
Agios Pharmaceutical Inc. (NASDAQ:AGIO) has withdrawn its European Marketing Authorization Application (MAA) for TIBSOVO® in treating refractory or relapsed acute myeloid leukemia patients with...
OncoCyte Corp (NYSEAMERICAN:OCX) Provides Update On DetermaRx’s Global Growth And Adoption
OncoCyte Corp (NYSEAMERICAN:OCX) provided a growth and adoption update on its non-small cell lung cancer (NSCLC) treatment stratification test called DetermaRx towards the end...
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Substantial Progress In Improving Lives Of Patients With Cancer...
Karyopharm Therapeutics Inc (NASDAQ:KPTI) achieved significant progress in making cancer patients’ lives better with the receipt of FDA approval for its drug – XPOVIO.
Approval...
MAKE IT MODERN
[/tdc_zone]